Incorporation of gene therapies, such as Beqvez (Pfizer),Hemgenix (CSL Behring) and Roctavian (BioMarin), and potential future approvalsof fitusiran (Sanofi) and
Following positive topline results from the Phase III REGENCY trial, Gazyva is positioned to compete with Benlysta and Lupkynis in
AbbVie now faces a more seasoned rival than Eli Lilly. (AbbVie) Spherix Global Insights said AbbVie’s Skyrizi has quickly blasted
Despite keen interest in BAFF-R inhibition, rheumatologists favor BMS’ Sotyktu (deucravacitinib) as the leading therapy in development for Sjögren’s. EXTON,
With Tremfya also securing approval in UC earlier this month, competition promises to be fierce among the IL-23s, according to
Comprehensive market insights across over 40 indications in dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology, providing financial firms with
Spherix Global Insights looked at which biosimilar brands stand to benefit as AbbVie loses access. (AbbVie) AbbVie reported global Humira sales of
US gastroenterologists more in favor of biosimilars than rheumatology and dermatology counterparts. EXTON, PA., September 23, 2024 — Spherix Global
Biogen’s litifilimab “stands out as an especially strong competitor” to Benlysta and Saphnelo, according to Spherix Global Insights analysts. New
Despite favorable views on litifilimab, AbbVie’s Rinvoqand BMS’ Sotyktu capture the most prescriber interest for approval, accordingto Spherix Global Insights.
While reported use of Sanofi/Regeneron’s Dupixent has declined with the adoption of LEO’s Adbry, Pfizer’s Cibinqo, and AbbVie’s Rinvoq, the
Analysts expect the companies’ Vabysmo and Eylea HD to generate a combined $13.2 billion by 2030 in the vascular endothelial
